Nature of the Business and Basis of Presentation (Details) - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Mar. 18, 2021 |
Jul. 20, 2018 |
Mar. 31, 2021 |
Mar. 31, 2020 |
Dec. 31, 2020 |
|
| Sale of Equity | |||||
| Net proceeds after deducting underwriting discounts and commissions | $ 188,000 | ||||
| Estimated offering cost | 800 | ||||
| Net Loss | (42,330) | $ (48,486) | $ (167,700) | ||
| Accumulated deficit | $ (522,801) | $ (480,471) | |||
| Common stock | |||||
| Sale of Equity | |||||
| Shares issued (in shares) | 6,896,552 | ||||
| Conversion of redeemable convertible preferred stock to common stock (in shares) | 51,845,438 | ||||
| IPO | |||||
| Sale of Equity | |||||
| Shares issued (in shares) | 12,055,450 | ||||
| Net proceeds after deducting underwriting discounts and commissions | $ 254,300 | ||||
| Offering | |||||
| Sale of Equity | |||||
| Shares issued (in shares) | 6,896,552 | ||||
| Net proceeds after deducting underwriting discounts and commissions | $ 188,000 | ||||
| Estimated offering cost | $ 800 | ||||
| Overallotment | |||||
| Sale of Equity | |||||
| Shares issued (in shares) | 1,572,450 | ||||